Onivyde for the therapy of multiple solid tumors

Area of Science:

• Nanobiotechnology
• Oncology
• Drug Delivery Systems

Background:

• Nanobiotechnology drug delivery systems enhance the pharmacokinetics and therapeutic index of chemotherapy agents.
• Onivyde (MM-398/PEP02) is a nanoliposomal irinotecan formulation demonstrating significant anticancer activity.
• This approach has revolutionized tumor therapy, offering improved treatment options.

Purpose of the Study:

• To review the structure, pharmacokinetics, and pharmacogenetics of Onivyde.
• To summarize clinical trial data for Onivyde in various malignancies.
• To recommend Onivyde for patients with advanced solid tumors.

Main Methods:

• Literature review of nanobiotechnology in drug delivery.
• Analysis of Onivyde's formulation and properties.
• Synthesis of data from clinical trials involving Onivyde.

Main Results:

• Onivyde exhibits encouraging anticancer activity across pancreatic, esophago-gastric, and colorectal cancers.
• The nanoliposomal formulation improves irinotecan's therapeutic profile.
• Clinical trials support its efficacy in advanced solid tumors.

Conclusions:

• Onivyde represents a significant advancement in nanobiotechnology-based cancer therapy.
• Its favorable pharmacokinetic and pharmacogenetic profile supports its use.
• Onivyde is recommended for patients with advanced solid tumors, particularly pancreatic cancer.